167 related articles for article (PubMed ID: 36970726)
1. Targeting MLL Methyltransferases Enhances the Antitumor Effects of PI3K Inhibition in Hormone Receptor-positive Breast Cancer.
Jones RB; Farhi J; Adams M; Parwani KK; Cooper GW; Zecevic M; Lee RS; Hong AL; Spangle JM
Cancer Res Commun; 2022 Dec; 2(12):1569-1578. PubMed ID: 36970726
[TBL] [Abstract][Full Text] [Related]
2. Methylation of the chromatin modifier KMT2D by SMYD2 contributes to therapeutic response in hormone-dependent breast cancer.
Blawski R; Vokshi BH; Guo X; Kittane S; Sallaku M; Chen W; Gjyzari M; Cheung T; Zhang Y; Simpkins C; Zhou W; Kulick A; Zhao P; Wei M; Shivashankar P; Prioleau T; Razavi P; Koche R; Rebecca VW; de Stanchina E; Castel P; Chan HM; Scaltriti M; Cocco E; Ji H; Luo M; Toska E
Cell Rep; 2024 May; 43(5):114174. PubMed ID: 38700982
[TBL] [Abstract][Full Text] [Related]
3. PI3K/AKT Signaling Regulates H3K4 Methylation in Breast Cancer.
Spangle JM; Dreijerink KM; Groner AC; Cheng H; Ohlson CE; Reyes J; Lin CY; Bradner J; Zhao JJ; Roberts TM; Brown M
Cell Rep; 2016 Jun; 15(12):2692-704. PubMed ID: 27292631
[TBL] [Abstract][Full Text] [Related]
4. PI3K Inhibition Activates SGK1 via a Feedback Loop to Promote Chromatin-Based Regulation of ER-Dependent Gene Expression.
Toska E; Castel P; Chhangawala S; Arruabarrena-Aristorena A; Chan C; Hristidis VC; Cocco E; Sallaku M; Xu G; Park J; Minuesa G; Shifman SG; Socci ND; Koche R; Leslie CS; Scaltriti M; Baselga J
Cell Rep; 2019 Apr; 27(1):294-306.e5. PubMed ID: 30943409
[TBL] [Abstract][Full Text] [Related]
5. Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications.
Vernieri C; Corti F; Nichetti F; Ligorio F; Manglaviti S; Zattarin E; Rea CG; Capri G; Bianchi GV; de Braud F
Breast Cancer Res; 2020 Apr; 22(1):33. PubMed ID: 32252811
[TBL] [Abstract][Full Text] [Related]
6. Structural basis of nucleosome recognition and modification by MLL methyltransferases.
Xue H; Yao T; Cao M; Zhu G; Li Y; Yuan G; Chen Y; Lei M; Huang J
Nature; 2019 Sep; 573(7774):445-449. PubMed ID: 31485071
[TBL] [Abstract][Full Text] [Related]
7. Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT.
O'Brien NA; McDonald K; Tong L; von Euw E; Kalous O; Conklin D; Hurvitz SA; di Tomaso E; Schnell C; Linnartz R; Finn RS; Hirawat S; Slamon DJ
Clin Cancer Res; 2014 Jul; 20(13):3507-20. PubMed ID: 24879796
[TBL] [Abstract][Full Text] [Related]
8. Global analysis of H3K4 methylation defines MLL family member targets and points to a role for MLL1-mediated H3K4 methylation in the regulation of transcriptional initiation by RNA polymerase II.
Wang P; Lin C; Smith ER; Guo H; Sanderson BW; Wu M; Gogol M; Alexander T; Seidel C; Wiedemann LM; Ge K; Krumlauf R; Shilatifard A
Mol Cell Biol; 2009 Nov; 29(22):6074-85. PubMed ID: 19703992
[TBL] [Abstract][Full Text] [Related]
9. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
[TBL] [Abstract][Full Text] [Related]
10. PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D.
Toska E; Osmanbeyoglu HU; Castel P; Chan C; Hendrickson RC; Elkabets M; Dickler MN; Scaltriti M; Leslie CS; Armstrong SA; Baselga J
Science; 2017 Mar; 355(6331):1324-1330. PubMed ID: 28336670
[TBL] [Abstract][Full Text] [Related]
11. Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer.
Ciruelos Gil EM
Cancer Treat Rev; 2014 Aug; 40(7):862-71. PubMed ID: 24774538
[TBL] [Abstract][Full Text] [Related]
12. MLL3 Induced by Luteolin Causes Apoptosis in Tamoxifen-Resistant Breast Cancer Cells through H3K4 Monomethylation and Suppression of the PI3K/AKT/mTOR Pathway.
Wu HT; Liu YE; Hsu KW; Wang YF; Chan YC; Chen Y; Chen DR
Am J Chin Med; 2020; 48(5):1221-1241. PubMed ID: 32668964
[TBL] [Abstract][Full Text] [Related]
13. Histone methyltransferase MLL1 regulates MDR1 transcription and chemoresistance.
Huo H; Magro PG; Pietsch EC; Patel BB; Scotto KW
Cancer Res; 2010 Nov; 70(21):8726-35. PubMed ID: 20861184
[TBL] [Abstract][Full Text] [Related]
14. Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer.
Alves CL; Ditzel HJ
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901954
[TBL] [Abstract][Full Text] [Related]
15. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
Fu X; Creighton CJ; Biswal NC; Kumar V; Shea M; Herrera S; Contreras A; Gutierrez C; Wang T; Nanda S; Giuliano M; Morrison G; Nardone A; Karlin KL; Westbrook TF; Heiser LM; Anur P; Spellman P; Guichard SM; Smith PD; Davies BR; Klinowska T; Lee AV; Mills GB; Rimawi MF; Hilsenbeck SG; Gray JW; Joshi A; Osborne CK; Schiff R
Breast Cancer Res; 2014 Sep; 16(5):430. PubMed ID: 25212826
[TBL] [Abstract][Full Text] [Related]
16. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation.
Fox EM; Kuba MG; Miller TW; Davies BR; Arteaga CL
Breast Cancer Res; 2013; 15(4):R55. PubMed ID: 23844554
[TBL] [Abstract][Full Text] [Related]
17. P110α inhibitor alpelisib exhibits a synergistic effect with pyrotinib and reverses pyrotinib resistant in HER2+ breast cancer.
Chen H; Si Y; Wen J; Hu C; Xia E; Wang Y; Wang O
Neoplasia; 2023 Sep; 43():100913. PubMed ID: 37348428
[TBL] [Abstract][Full Text] [Related]
18. [Expert consensus on the clinical application of PI3K/AKT/mTOR inhibitors in the treatment of advanced breast cancer].
; ; ;
Zhonghua Zhong Liu Za Zhi; 2022 Jul; 44(7):673-692. PubMed ID: 35880333
[TBL] [Abstract][Full Text] [Related]
19. Molecular Insights of Pathways Resulting from Two Common PIK3CA Mutations in Breast Cancer.
Bhat-Nakshatri P; Goswami CP; Badve S; Magnani L; Lupien M; Nakshatri H
Cancer Res; 2016 Jul; 76(13):3989-4001. PubMed ID: 27197157
[TBL] [Abstract][Full Text] [Related]
20. Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.
O'Brien NA; McDermott MSJ; Conklin D; Luo T; Ayala R; Salgar S; Chau K; DiTomaso E; Babbar N; Su F; Gaither A; Hurvitz SA; Linnartz R; Rose K; Hirawat S; Slamon DJ
Breast Cancer Res; 2020 Aug; 22(1):89. PubMed ID: 32795346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
